• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Abbott shares down on shrinking Q1 profits

Abbott shares down on shrinking Q1 profits

April 18, 2018 By Fink Densford

Abbott logo

Shares in Abbott (NYSE:ABT) fell today after the medical device maker beat expectations on Wall Street but saw profits shrink in its first quarter earnings release.

The Abbott Park, Ill.-based company posted profits of $418 million, or 23¢ per share, on sales of approximately $7.4 billion for the three months ended March 31, seeing the bottom line shrink 0.2% while sales grew 16.7%.

Adjusted to exclude one-time items, earnings per share were 59¢, just ahead of the 58¢ consensus on Wall Street where analysts expected to see sales of $7.3 billion for the quarter.

“We’re off to a strong start to the year as we forecasted. We’re particularly pleased with the continued strong growth in Medical Devices and improving performance in our Nutrition business,” chair & CEO Miles White said in a prepared statement.

Abbott released updated guidance for the year, expecting to see diluted EPS for the year of between $1.23 and $1.33. Non-GAAP EPS from continuing operations is expected to be between $2.80 and $2.90.

For its next quarter, Abbott said it expects to post GAAP EPS of 33¢ and 35¢, with non-GAAP EPS of between 70¢ and 72¢.

Shares in Abbott have fallen 2.1% so far today, at $58.53 as of 10:03 a.m. EDT.

Filed Under: Business/Financial News, MassDevice Earnings Roundup Tagged With: Abbott

More recent news

  • Endologix is now Rhevera Medical
  • iRhythm completes acquisition of VitalConnect
  • Medtronic taps Siemens Healthineers exec as new Cardiac Ablations Solutions VP
  • Stryker will have a new CEO next year
  • Zenflow nets $52M, Cook Medical deal for in-office enlarged prostate implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy